
Jameel Nazir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5197927/publications.pdf Version: 2024-02-01



IMMEEL NAZID

#	Article	IF	CITATIONS
1	Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. Journal of Market Access & Health Policy, 2018, 6, 1438721.	1.5	4
2	Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. European Urology, 2018, 74, 324-333.	1.9	151
3	Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network metaâ€analysis. Neurourology and Urodynamics, 2018, 37, 986-996.	1.5	12
4	Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open, 2018, 8, e021889.	1.9	81
5	A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain. BMC Urology, 2018, 18, 76.	1.4	12
6	A critical appraisal of the principal guidelines for neurogenic lower urinary tract dysfunction using the AGREE II instrument. Neurourology and Urodynamics, 2018, 37, 2945-2950.	1.5	6
7	Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. European Urology, 2017, 72, 389-399.	1.9	162
8	Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada. Journal of Medical Economics, 2017, 20, 614-622.	2.1	10
9	Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database. International Journal of Clinical Practice, 2017, 71, e12996.	1.7	29
10	Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK. PharmacoEconomics - Open, 2017, 1, 25-36.	1.8	11
11	Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal, 2017, 11, 123.	0.6	10
12	Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom. Clinical Drug Investigation, 2015, 35, 83-93.	2.2	22
13	Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom. Value in Health, 2015, 18, 783-790.	0.3	28
14	Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. BMC Urology, 2015, 15, 41.	1.4	6
15	Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service. Journal of Medical Economics, 2015, 18, 390-397.	2.1	8
16	Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data. Current Medical Research and Opinion, 2015, 31, 43-50.	1.9	20
17	Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison. European Urology, 2014, 65, 755-765.	1.9	223
18	Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder. Health and Quality of Life Outcomes, 2013, 11, 200.	2.4	24